All In Biotech

Drug Trial Radar · NCT07257835

Dupilumab Therapy for EGIDs

Dupilumab Therapy for Refractory Eosinophilic Gastrointestinal Disorders in Children

Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jan 1, 2025

Primary completion

Jan 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Children's Hospital of Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.

Conditions

  • Eosinophilic Gastrointestinal Disorders (EGIDs)

Interventions

  • Dupilumab - Standard DoseDrug

    Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.

  • subcutaneous injectionDevice

    Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endoscopic response rateTime frame: week12, week26, week52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 201102

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.